Related Experiment Video

Updated: Oct 12, 2026

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Low serum levels of tumor necrosis factor-alpha in insulin-dependent diabetic children

R Lorini1, M De Amici, G d'Annunzio

  • 1Department of Pediatrics, University of Pavia-IRCCS Policlinico S. Matteo, Italy.

Hormone Research
|January 1, 1995
PubMed

Insights

Children with insulin-dependent diabetes mellitus (IDDM) have lower tumor necrosis factor-alpha (TNF-alpha) levels than healthy individuals. These lower TNF-alpha levels in IDDM patients may contribute to immune dysregulation and the development of autoimmune diseases.

Area of Science:

  • Immunology
  • Endocrinology
  • Pediatrics

Background:

  • Tumor necrosis factor-alpha (TNF-alpha) is a cytokine involved in immune regulation.
  • Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease characterized by the destruction of pancreatic beta cells.
  • Aberrant cytokine production may play a role in the pathogenesis of autoimmune diseases.

Purpose of the Study:

  • To investigate serum levels of TNF-alpha in children with IDDM.
  • To compare TNF-alpha levels in IDDM patients with healthy controls.
  • To explore the relationship between TNF-alpha levels and disease characteristics in IDDM.

Main Methods:

  • Serum TNF-alpha levels were measured using immunoradiometric assay.
  • 48 children with IDDM were divided into two groups based on disease duration (< 6 months and > 3 years).
  • 36 age- and sex-matched healthy subjects served as controls.

Main Results:

  • Serum TNF-alpha levels were significantly lower in all IDDM patients compared to controls (p < 0.0001).
  • Lower TNF-alpha levels were observed in both short-term (< 6 months) and long-term (> 3 years) IDDM groups compared to controls.
  • TNF-alpha levels were lower in IDDM patients with antibodies than in those without antibodies and controls.
  • No correlation was found between serum TNF-alpha and age, disease duration, metabolic control, insulin requirement, or HLA typing.
  • No significant variations in TNF-alpha levels were observed during a 1-year follow-up in a subset of patients.

Conclusions:

  • Children with IDDM exhibit reduced serum TNF-alpha levels.
  • Aberrant TNF-alpha synthesis might contribute to immune dysregulation, potentially favoring the development of autoimmune diseases like IDDM.
  • Further research is warranted to elucidate the role of TNF-alpha in IDDM pathogenesis.

More Related Videos

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...